Esperion Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Esperion Therapeutics

05/08/2025 14:31

Esperion Therapeutics Inc ESPR.OQ reported a quarterly adjusted loss of 2 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -33 cents.  The mean expectation of eight analysts for the quarter was for a loss of 13 cents per share. Wall Street expected results to range from -19 cents tozero cents per share.

Revenue rose 11.6% to $82.39 million from a year ago; analysts expected $63.05 million.

Esperion Therapeutics Inc's reported EPS for the quarter was a loss of 2 cents​.

The company reported a quarterly loss of $61.93 million.

Esperion Therapeutics Inc shares had risen by 51.4% this quarter and lost 32.3% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Esperion Therapeutics Inc is $4.00, about 62.7% above its last closing price of $1.49

This summary was machine generated from LSEG data August 5 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-0.13
-0.02
Beat
Mar. 31 2025
-0.15
-0.21
Missed
Dec. 31 2024
-0.15
-0.11
Beat
Sep. 30 2024
-0.18
-0.15
Beat